Creative BioMart to Present at BPS 2025 Annual Meeting | February 15-19, 2025

Active Recombinant Human CD19 protein, His-tagged, R-PE labeled

Cat.No. : CD19-3309HP
Product Overview : Recombinant Human CD19 protein, His-tagged was Conjugated with NH2-Reactive R-PE(R-Phycoerythrin).
Availability February 16, 2025
Unit
Price
Qty
  • Specification
  • Gene Information
  • Related Products
  • Download
Source : HEK293
Species : Human
Tag : His
Form : Lyophilized from sterile 50 mM Tris, pH 8.0.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Bio-activity : Immobilized Human CD19 His at 2 μg/ml (100 μl/well) can bind Anti-CD19 Antibody, the EC50 of Anti-CD19 Antibody is 5-40 ng/mL.
Molecular Mass : The recombinant human CD19 consists of 283 amino acids and predictes a molecular mass of 31.6 kDa. In SDS-PAGE under reducing conditions, rhCD19 migrates as an approximately 47 kDa band due to glycosylation.
Protein length : Met1-Lys291
Endotoxin : < 1.0 EU per μg protein as determined by the LAL method.
Purity : > 90 % as determined by SDS-PAGE.
Storage : Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution : It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.
Publication :
Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization (2019)
Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells (2022)
Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors (2021)
Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy (2023)
Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells (2017)
Gene Name : CD19 CD19 molecule [ Homo sapiens ]
Official Symbol : CD19
Synonyms : CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
Gene ID : 930
mRNA Refseq : NM_001178098
Protein Refseq : NP_001171569
MIM : 107265
UniProt ID : P15391

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
01/02/2023

    The manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.

    08/18/2022

      This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.

      06/29/2016

        Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.

        Q&As (5)

        Ask a question
        How does CAR-T cell therapy work to combat CD19-expressing cancers? 02/11/2023

        CAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.

        Are there any diseases associated with CD19 dysfunction? 12/07/2022

        CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.

        What are the potential side effects of CAR-T cell therapy targeting CD19? 01/26/2022

        Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.

        What are some CD19-expressing malignancies that CAR-T cell therapy can target? 07/17/2021

        CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.

        How effective is CAR-T cell therapy in treating CD19-expressing cancers? 08/26/2019

        CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.

        Ask a Question for All CD19 Products

        Required fields are marked with *

        My Review for All CD19 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2025 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends